PubRank

Zhonghong Guan

Author PubWeight™ 40.74‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006 4.15
2 Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2008 2.84
3 Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol 2008 2.58
4 Age related pathogenesis of nocturia in patients with overactive bladder. J Urol 2007 1.57
5 Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int 2009 1.46
6 Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008 1.41
7 Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int 2011 1.31
8 Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008 1.16
9 Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006 1.12
10 Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review. Eur Urol 2010 1.04
11 Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010 1.01
12 Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008 0.97
13 Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006 0.94
14 Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 2010 0.94
15 Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 2006 0.92
16 Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. BJU Int 2006 0.87
17 Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2009 0.87
18 Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2006 0.86
19 Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct 2008 0.85
20 Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology 2009 0.84
21 Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008 0.84
22 Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodyn 2011 0.84
23 Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int 2010 0.83
24 Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int 2006 0.82
25 Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol 2009 0.82
26 The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J 2011 0.80
27 Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration. BJU Int 2010 0.80
28 Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007 0.79
29 Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Curr Med Res Opin 2008 0.78
30 Effects of combined behavioral intervention and tolterodine on patient-reported outcomes. Can J Urol 2010 0.78
31 Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Curr Med Res Opin 2009 0.78
32 Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology 2008 0.78
33 Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging 2012 0.77
34 Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. Curr Med Res Opin 2011 0.77
35 Efficacy of fesoterodine over 24 hours in subjects with overactive bladder. Curr Med Res Opin 2010 0.77
36 The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU Int 2007 0.76
37 The effect of elective sham dose escalation on the placebo response during an antimuscarinic trial for overactive bladder symptoms. J Urol 2012 0.76
38 Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. BMC Urol 2010 0.76